Reporting on multidrug-resistant tuberculosis: A proposed definition for the treatment outcome 'failed'

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 5, 2009, Pages 548-550

  Chiang, C Y ^a,b   Caminero, J A ^a   Enarson, D A ^a  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^b NONE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE;

DECISION MAKING; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT SURVEY; SPUTUM ANALYSIS; SPUTUM CULTURE; SPUTUM SMEAR; TREATMENT DURATION; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; HUMANS; INCIDENCE; MANDATORY REPORTING; OUTCOME ASSESSMENT (HEALTH CARE); POPULATION SURVEILLANCE; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH;

EID: 67649513154     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (18)

1. World Health Organization. Guidelines of the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. Geneva, Switzerland: WHO, 2006.
2. Laserson K F, Thorpe L E, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645.
3. Burgos M, Gonzalez L C, Paz E A, et al. Treatment of multidrugresistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis 2005; 40: 968-975.
4. Geerligs W A, van Altena R, de Lange W C M, van Soolingen D, van der Werf T S. Multidrug-resistant tuberculosis: longterm treatment outcome in the Netherlands. Int J Tuberc Lung Dis 2000; 4: 758-764.
5. Flament-Saillour M, Robert J, Jarlier V, Grosset J. Outcome of multidrug-resistant tuberculosis in France. A nationwide casecontrol study. Am J Respir Crit Care Med 1999; 160: 587-593.
6. Van Deun A, Hamid Salim M A, Kumar Das A P, Bastian I, Portaels F. Results of a standardised regimen for multidrugresistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004; 8: 560-567.
7. Chiang C-Y, Enarson D A, Yu M-C, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 2006; 28: 980-985.
8. Suárez P G, Floyd K, Portocarrero J, et al. Feasibility and costeffectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359: 1980-1989.
9. Chan E D, Laurel V, Strand M J, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-1109.
10. Tahaoglu K, Törün T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174.
11. Kim H J, Hong Y P, Kim S J, Lew W J, Lee E G. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. Int J Tuberc Lung Dis 2001; 5: 1129-1136.
12. Leimane V, Riekstina V, Holtz T H, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326.
13. Nathanson E, Lambregts van Weezenbeek C, Rich M L, et al. Multidrug-resistant tuberculosis management in resourcelimited settings. Emerg Infect Dis 2006; 12: 1389-1397.
14. Mitnick C D, Shin S S, Seung K J, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-674.
15. Enarson D A, Rieder H L, Arnadottir T, Trébucq A. Management of tuberculosis. A guide for low-income countries. 5th ed. Paris, France: International Union Against Tuberculosis and Lung Disease, 2000.
16. Holtz T H, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006; 144: 650-659.
17. Ginsburg A S, Grosset J H, Bishai W R. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003; 3: 432-442.
18. Johnson J L, Hadad D J, Boom W H, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10:605-612.